Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 4/2007

01.04.2007 | Review

Antimicrobial therapy for Stenotrophomonas maltophilia infections

verfasst von: A. C. Nicodemo, J. I. Garcia Paez

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Stenotrophomonas maltophilia has emerged as an important nosocomial pathogen capable of causing respiratory, bloodstream, and urinary infections. The treatment of nosocomial infections by S. maltophilia is difficult, as this pathogen shows high levels of intrinsic or acquired resistance to different antimicrobial agents, drastically reducing the antibiotic options available for treatment. Intrinsic resistance may be due to reduced outer membrane permeability or to the multidrug efflux pumps. However, specific mechanisms of resistance such as aminoglycoside-modifying enzymes or the heterogeneous production of metallo-β-lactamase have contributed to the multidrug-resistant phenotype displayed by this pathogen. Moreover, the lack of standardized susceptibility tests and their interpretative criteria hinder the choice of an adequate antibiotic treatment. Recommendations for the treatment of infections by S. maltophilia are based on in vitro studies, certain nonrandomized clinical trials, and anecdotal experience. Trimethoprim-sulfamethoxazole remains the drug of choice, although in vitro studies indicate that ticarcillin-clavulanic acid, minocycline, some of the new fluoroquinolones, and tigecycline may be useful agents. This review describes the main resistance mechanisms, the in vitro susceptibility profile, and treatment options for S. maltophilia infections.
Literatur
1.
Zurück zum Zitat Hugh R, Gilardi GL (1980) Pseudomonas. In: Lennette EH, Balows A, Hausler WJ, Truant JP (eds) Manual of clinical microbiology, 3rd edn. American Society for Microbiology, Washington DC, pp 288–317 Hugh R, Gilardi GL (1980) Pseudomonas. In: Lennette EH, Balows A, Hausler WJ, Truant JP (eds) Manual of clinical microbiology, 3rd edn. American Society for Microbiology, Washington DC, pp 288–317
2.
Zurück zum Zitat Hugh R, Ryschenkow E (1961) Pseudomonas maltophilia, an Alcaligenes-like species. J Gen Microbiol 26:123–132PubMed Hugh R, Ryschenkow E (1961) Pseudomonas maltophilia, an Alcaligenes-like species. J Gen Microbiol 26:123–132PubMed
3.
Zurück zum Zitat Swings J, De Vos P, Van den Mooter M, De Ley J (1983) Transfer of Pseudomonas maltophilia Hugh 1981 to the genus Xanthomonas as Xanthomonas maltophilia (Hugh 1981) comb. nov. Int J Syst Bacteriol 33:409–413 Swings J, De Vos P, Van den Mooter M, De Ley J (1983) Transfer of Pseudomonas maltophilia Hugh 1981 to the genus Xanthomonas as Xanthomonas maltophilia (Hugh 1981) comb. nov. Int J Syst Bacteriol 33:409–413
4.
Zurück zum Zitat Palleroni NJ, Bradbury JF (1983) Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al (1983). Int J Syst Bacteriol 43:606–609CrossRef Palleroni NJ, Bradbury JF (1983) Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al (1983). Int J Syst Bacteriol 43:606–609CrossRef
5.
Zurück zum Zitat Gilardi GL (1969) Pseudomonas maltophilia infections in man. Am J Clin Pathol 51:58–61PubMed Gilardi GL (1969) Pseudomonas maltophilia infections in man. Am J Clin Pathol 51:58–61PubMed
6.
Zurück zum Zitat Denton M, Kerr KG (1998) Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 11:57–80PubMed Denton M, Kerr KG (1998) Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 11:57–80PubMed
7.
Zurück zum Zitat Bottone EJ, Reitano M, Janda JM, Troy K, Cuttner J (1986) Pseudomonas maltophilia exoenzyme activity as correlate in pathogenesis of ecthyma gangrenosum. J Clin Microbiol 24:995–997PubMed Bottone EJ, Reitano M, Janda JM, Troy K, Cuttner J (1986) Pseudomonas maltophilia exoenzyme activity as correlate in pathogenesis of ecthyma gangrenosum. J Clin Microbiol 24:995–997PubMed
8.
Zurück zum Zitat Jucker BA, Harms H, Zehnder AJ (1996) Adhesion of the positively charged bacterium Stenotrophomonas (Xanthomonas) maltophilia 70401 to glass and teflon. J Bacteriol 178:5472–5479PubMed Jucker BA, Harms H, Zehnder AJ (1996) Adhesion of the positively charged bacterium Stenotrophomonas (Xanthomonas) maltophilia 70401 to glass and teflon. J Bacteriol 178:5472–5479PubMed
9.
Zurück zum Zitat de Oliveira-Garcia D, Dall’Agnol M, Rosales M, Azzuz AC, Alcantara N, Martinez MB, Giron JA (2003) Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces. Cell Microbiol 5:625–636PubMedCrossRef de Oliveira-Garcia D, Dall’Agnol M, Rosales M, Azzuz AC, Alcantara N, Martinez MB, Giron JA (2003) Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces. Cell Microbiol 5:625–636PubMedCrossRef
10.
Zurück zum Zitat Di Bonaventura G, Spedicato I, D’Antonio D, Robuffo I, Piccolomini R (2004) Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother 48:151–160PubMedCrossRef Di Bonaventura G, Spedicato I, D’Antonio D, Robuffo I, Piccolomini R (2004) Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother 48:151–160PubMedCrossRef
11.
Zurück zum Zitat Morrison AJ Jr, Hoffmann KK, Wenzel RP (1986) Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 24:52–55PubMed Morrison AJ Jr, Hoffmann KK, Wenzel RP (1986) Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 24:52–55PubMed
12.
Zurück zum Zitat del Toro MD, Rodriguez-Bano J, Herrero M, Rivero A, Garcia-Ordonez MA, Corzo J, Peres-Cano R, Grupo Andaluz para El Estudio de las Enfermedades Infecciosas (2002) Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine (Baltimore) 81:228–239CrossRef del Toro MD, Rodriguez-Bano J, Herrero M, Rivero A, Garcia-Ordonez MA, Corzo J, Peres-Cano R, Grupo Andaluz para El Estudio de las Enfermedades Infecciosas (2002) Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine (Baltimore) 81:228–239CrossRef
13.
Zurück zum Zitat Senol E, DesJardin J, Stark PC, Barefort L, Snydman DR (2002) Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 34:1653–1656PubMedCrossRef Senol E, DesJardin J, Stark PC, Barefort L, Snydman DR (2002) Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 34:1653–1656PubMedCrossRef
14.
Zurück zum Zitat Murder RR, Harris AP, Muller, Edmond M, Chow JW, Papadakis K, Wagner MW, Bodey GP, Steckelberg JM (1996) Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 22:508–512 Murder RR, Harris AP, Muller, Edmond M, Chow JW, Papadakis K, Wagner MW, Bodey GP, Steckelberg JM (1996) Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 22:508–512
15.
Zurück zum Zitat Carmeli Y, Samore MH (1997) Comparison of treatment with imipenem vs ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis 24:1131–1134PubMed Carmeli Y, Samore MH (1997) Comparison of treatment with imipenem vs ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis 24:1131–1134PubMed
16.
Zurück zum Zitat Talmaciu I, Varlota L, Mortensen J, Schidlow DV (2000) Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 30:10–15PubMedCrossRef Talmaciu I, Varlota L, Mortensen J, Schidlow DV (2000) Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 30:10–15PubMedCrossRef
17.
Zurück zum Zitat Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, Fabian TC (2002) Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 35:228–235PubMedCrossRef Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, Fabian TC (2002) Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 35:228–235PubMedCrossRef
18.
Zurück zum Zitat Elting LS, Khardori N, Bodey GP, Fainstein V (1990) Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 11:134–138PubMed Elting LS, Khardori N, Bodey GP, Fainstein V (1990) Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 11:134–138PubMed
19.
Zurück zum Zitat Micozzi A, Venditti M, Monaco M, Friedrich A, Taglietti F, Santilli S, Martino P (2000) Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 31:705–711PubMedCrossRef Micozzi A, Venditti M, Monaco M, Friedrich A, Taglietti F, Santilli S, Martino P (2000) Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 31:705–711PubMedCrossRef
20.
Zurück zum Zitat Villarino ME, Stevens LE, Schable B, Mayers G, Miller JM, Burke JP, Jarvis WR (1992) Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 13:201–206PubMedCrossRef Villarino ME, Stevens LE, Schable B, Mayers G, Miller JM, Burke JP, Jarvis WR (1992) Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 13:201–206PubMedCrossRef
21.
Zurück zum Zitat Apisarnthanarak A, Mayfield JL, Garison T, McLendon PM, Di Persio JF, Frasere VJ, Polish LB (2003) Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol 24:269–274PubMedCrossRef Apisarnthanarak A, Mayfield JL, Garison T, McLendon PM, Di Persio JF, Frasere VJ, Polish LB (2003) Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol 24:269–274PubMedCrossRef
22.
Zurück zum Zitat Victor MA, Arpi M, Bruun B, Jonsson V, Hansen MM (1994) Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis 26:163–170PubMed Victor MA, Arpi M, Bruun B, Jonsson V, Hansen MM (1994) Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis 26:163–170PubMed
23.
Zurück zum Zitat Senol E (2004) Stenotrophomonas malthophilia: the significance and role as a nosocomial pathogen. J Hosp Infect 57:1–7PubMedCrossRef Senol E (2004) Stenotrophomonas malthophilia: the significance and role as a nosocomial pathogen. J Hosp Infect 57:1–7PubMedCrossRef
24.
Zurück zum Zitat Friedman ND, Korman TM, Franklin JC, Spelman DW (2002) Bacteremia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 45:47–53PubMedCrossRef Friedman ND, Korman TM, Franklin JC, Spelman DW (2002) Bacteremia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 45:47–53PubMedCrossRef
25.
Zurück zum Zitat Crum NF, Utz GC, Wallace MR (2002) Stenotrophomonas maltophilia endocarditis. Scand J Infect Dis 34:925–927PubMedCrossRef Crum NF, Utz GC, Wallace MR (2002) Stenotrophomonas maltophilia endocarditis. Scand J Infect Dis 34:925–927PubMedCrossRef
26.
Zurück zum Zitat Padilla D, Cubo T, Romero MD, Pardo R, Martin J, Chmielewski J, Hernandez J (2002) Infección nosocomial por Stenotrophomonas maltophilia en enfermos intervenidos quirúrgicamente. Enferm Infecc Microbiol Clin 20:187–190 Padilla D, Cubo T, Romero MD, Pardo R, Martin J, Chmielewski J, Hernandez J (2002) Infección nosocomial por Stenotrophomonas maltophilia en enfermos intervenidos quirúrgicamente. Enferm Infecc Microbiol Clin 20:187–190
27.
Zurück zum Zitat Platsouka E, Routsi C, Chalkis A, Dimitriadou E, Paniara O, Roussos C (2002) Stenotrophomonas maltophilia meningitis, bacteremia and respiratory infection. Scand J Infect Dis 34:391–392PubMedCrossRef Platsouka E, Routsi C, Chalkis A, Dimitriadou E, Paniara O, Roussos C (2002) Stenotrophomonas maltophilia meningitis, bacteremia and respiratory infection. Scand J Infect Dis 34:391–392PubMedCrossRef
28.
Zurück zum Zitat Sakhnini E, Weissmann A, Oren I (2002) Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromised patients: an outbreak transmitted via tap water. Am J Med Sci 323:269–272PubMedCrossRef Sakhnini E, Weissmann A, Oren I (2002) Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromised patients: an outbreak transmitted via tap water. Am J Med Sci 323:269–272PubMedCrossRef
29.
Zurück zum Zitat Moser C, Jonsson V, Thomsen K, Albrectsen J, Hansen MM, Prag J (1997) Subcutaneous lesions and bacteremia due to Stenotrophomonas maltophilia in three leukaemic patients with neutropenia. Br J Dermatol 136:949–952PubMedCrossRef Moser C, Jonsson V, Thomsen K, Albrectsen J, Hansen MM, Prag J (1997) Subcutaneous lesions and bacteremia due to Stenotrophomonas maltophilia in three leukaemic patients with neutropenia. Br J Dermatol 136:949–952PubMedCrossRef
30.
Zurück zum Zitat Burns RL, Lowe L (1997) Xanthomonas maltophilia infection presenting as erythematous nodules. J Am Acad Dermatol 37:836–838PubMed Burns RL, Lowe L (1997) Xanthomonas maltophilia infection presenting as erythematous nodules. J Am Acad Dermatol 37:836–838PubMed
31.
Zurück zum Zitat Vartivarian SE, Papadakis KA, Anaissie EJ (1996) Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch Intern Med 156:433–435PubMedCrossRef Vartivarian SE, Papadakis KA, Anaissie EJ (1996) Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch Intern Med 156:433–435PubMedCrossRef
32.
Zurück zum Zitat Fujita J, Yamadori I, Xu G, Hojo S, Negayama K, Miyawaki H, Yamaji Y, Takahara J (1996) Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients. Respir Med 90:35–38PubMedCrossRef Fujita J, Yamadori I, Xu G, Hojo S, Negayama K, Miyawaki H, Yamaji Y, Takahara J (1996) Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients. Respir Med 90:35–38PubMedCrossRef
33.
Zurück zum Zitat Taylor G, McKenzie M, Buchanan-Chell M, Perry D, Chui L, Dasgupta M (1999) Peritonitis due to Stenotrophomonas maltophilia in patients undergoing chronic peritoneal dialysis. Perit Dial Int 19:259–262PubMed Taylor G, McKenzie M, Buchanan-Chell M, Perry D, Chui L, Dasgupta M (1999) Peritonitis due to Stenotrophomonas maltophilia in patients undergoing chronic peritoneal dialysis. Perit Dial Int 19:259–262PubMed
34.
Zurück zum Zitat Khan IA, Mehta NJ (2002) Stenotrophomonas maltophilia endocarditis: a systematic review. Angiology 53:49–55PubMedCrossRef Khan IA, Mehta NJ (2002) Stenotrophomonas maltophilia endocarditis: a systematic review. Angiology 53:49–55PubMedCrossRef
35.
Zurück zum Zitat Wang WS, Liu CP, Lee CM, Huang FY (2004) Bacteremia in adults: four years’ experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 37:359–365PubMed Wang WS, Liu CP, Lee CM, Huang FY (2004) Bacteremia in adults: four years’ experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 37:359–365PubMed
36.
Zurück zum Zitat Berg G, Roskot N, Smalla K (1999) Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia. J Clin Microbiol 37:3594–3600PubMed Berg G, Roskot N, Smalla K (1999) Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia. J Clin Microbiol 37:3594–3600PubMed
37.
Zurück zum Zitat Nicodemo AC, Araujo MRE, Ruiz AS, Gales AC (2004) In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, E test and agar dilution methods. J Antimicrob Chemother 53:604–608PubMedCrossRef Nicodemo AC, Araujo MRE, Ruiz AS, Gales AC (2004) In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, E test and agar dilution methods. J Antimicrob Chemother 53:604–608PubMedCrossRef
38.
Zurück zum Zitat Saino Y, Kobayashi F, Inoue M, Mitsuhashi S (1982) Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia. Antimicrob Agents Chemother 22:564–570PubMed Saino Y, Kobayashi F, Inoue M, Mitsuhashi S (1982) Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia. Antimicrob Agents Chemother 22:564–570PubMed
39.
Zurück zum Zitat Crowder MW, Walsh TR, Banovic L, Pettit M, Spencer J (1998) Overexpression, purification and characterization of the cloned metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 42:921–926PubMed Crowder MW, Walsh TR, Banovic L, Pettit M, Spencer J (1998) Overexpression, purification and characterization of the cloned metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 42:921–926PubMed
40.
Zurück zum Zitat Walsh TR, MacGowen AP, Bennett PM (1997) Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 41:1460–1464PubMed Walsh TR, MacGowen AP, Bennett PM (1997) Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 41:1460–1464PubMed
41.
Zurück zum Zitat Avison MB, Higgins CS, Von Heldreich CJ, Bennet PM, Walsh TR (2001) Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 45:413–419PubMedCrossRef Avison MB, Higgins CS, Von Heldreich CJ, Bennet PM, Walsh TR (2001) Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 45:413–419PubMedCrossRef
42.
Zurück zum Zitat Avison MB, Higgins CS, Ford PJ, von Heldreich CJ, Walsh TR, Bennet PM (2002) Differential regulation of L1 and L2 beta-lactamase expression in Stenotrophomonas maltophilia. J Antimicrob Chemother 49:387–389PubMedCrossRef Avison MB, Higgins CS, Ford PJ, von Heldreich CJ, Walsh TR, Bennet PM (2002) Differential regulation of L1 and L2 beta-lactamase expression in Stenotrophomonas maltophilia. J Antimicrob Chemother 49:387–389PubMedCrossRef
43.
Zurück zum Zitat Avison MB, Higgins CS, Von Heldreich CJ, Bennet PM, Walsh TR (2000) A TEM-2beta-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia. J Antimicrob Chemother 46:879–884PubMedCrossRef Avison MB, Higgins CS, Von Heldreich CJ, Bennet PM, Walsh TR (2000) A TEM-2beta-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia. J Antimicrob Chemother 46:879–884PubMedCrossRef
44.
Zurück zum Zitat Alonso A, Martinez JL (2000) Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 44:3079–3086PubMedCrossRef Alonso A, Martinez JL (2000) Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 44:3079–3086PubMedCrossRef
45.
Zurück zum Zitat Alonso A, Martinez JL (2001) Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 45:1879–1881PubMedCrossRef Alonso A, Martinez JL (2001) Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 45:1879–1881PubMedCrossRef
46.
Zurück zum Zitat Gould VC, Avison MB (2006) SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships. J Antimicrob Chemother 57:1070–1076PubMedCrossRef Gould VC, Avison MB (2006) SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships. J Antimicrob Chemother 57:1070–1076PubMedCrossRef
47.
Zurück zum Zitat Sánchez P, Alonso A, Martinez JL (2002) Cloning and characterization of the smeT, a repressor of the Stenotrophomonas maltophilia multidrug efflux pump smeDEF. Antimicrob Agents Chemother 46:3386–3393PubMedCrossRef Sánchez P, Alonso A, Martinez JL (2002) Cloning and characterization of the smeT, a repressor of the Stenotrophomonas maltophilia multidrug efflux pump smeDEF. Antimicrob Agents Chemother 46:3386–3393PubMedCrossRef
48.
Zurück zum Zitat Sánchez P, Alonso A, Martinez JL (2004) Regulatory regions of SmeDEF in Stenotrophomonas maltophilia strains expressing different amounts of the multidrug efflux pump smeDEF. Antimicrob Agents Chemother 48:2274–2276PubMedCrossRef Sánchez P, Alonso A, Martinez JL (2004) Regulatory regions of SmeDEF in Stenotrophomonas maltophilia strains expressing different amounts of the multidrug efflux pump smeDEF. Antimicrob Agents Chemother 48:2274–2276PubMedCrossRef
49.
Zurück zum Zitat Li XZ, Zhang L, Poole K (2002) SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 46:333–343PubMedCrossRef Li XZ, Zhang L, Poole K (2002) SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 46:333–343PubMedCrossRef
50.
Zurück zum Zitat Chang LL, Chen HF, Chang CY, Lee TM, Wu WJ (2004) Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 53:518–521PubMedCrossRef Chang LL, Chen HF, Chang CY, Lee TM, Wu WJ (2004) Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 53:518–521PubMedCrossRef
51.
Zurück zum Zitat Lambert T, Ploy MC, Denis F, Courvalin P (1999) Characterization of the chromosomal aac(6′)-Iz gene of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 43:2366–2371PubMed Lambert T, Ploy MC, Denis F, Courvalin P (1999) Characterization of the chromosomal aac(6′)-Iz gene of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 43:2366–2371PubMed
52.
Zurück zum Zitat Li XZ, Zhang L, McKay GA, Poole K (2003) Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J Antimicrob Chemother 51:803–811PubMedCrossRef Li XZ, Zhang L, McKay GA, Poole K (2003) Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J Antimicrob Chemother 51:803–811PubMedCrossRef
53.
Zurück zum Zitat Okazaki A, Avison MB (2004) Characterization of the Aph(3′)-IIa determinant of Stenotrophomonas maltophilia. In: 44th ICAAC, Abstract no. CI-1497 Okazaki A, Avison MB (2004) Characterization of the Aph(3′)-IIa determinant of Stenotrophomonas maltophilia. In: 44th ICAAC, Abstract no. CI-1497
54.
Zurück zum Zitat Poole K (2002) Outer membranes and efflux: the path to multidrug resistance in gram-negative bacteria. Curr Pharm Biotechnol 3:77–98PubMedCrossRef Poole K (2002) Outer membranes and efflux: the path to multidrug resistance in gram-negative bacteria. Curr Pharm Biotechnol 3:77–98PubMedCrossRef
55.
Zurück zum Zitat Wheat PF, Winstanley TG, Spencer RC (1985) Effect of temperature on antimicrobial susceptibilities of Pseudomonas maltophilia. J Clin Pathol 38:1055–1058PubMed Wheat PF, Winstanley TG, Spencer RC (1985) Effect of temperature on antimicrobial susceptibilities of Pseudomonas maltophilia. J Clin Pathol 38:1055–1058PubMed
56.
Zurück zum Zitat Rahmati-Bahram A, Magee JT, Jackson SK (1995) Temperature-dependent variation of cell envelope lipids and antibiotic susceptibility in Stenotrophomonas (Xanthomonas) maltophilia. J Antimicrob Chemother 36:317–326PubMedCrossRef Rahmati-Bahram A, Magee JT, Jackson SK (1995) Temperature-dependent variation of cell envelope lipids and antibiotic susceptibility in Stenotrophomonas (Xanthomonas) maltophilia. J Antimicrob Chemother 36:317–326PubMedCrossRef
57.
Zurück zum Zitat Rahmati-Bahram A, Magee JT, Jackson SK (1996) Temperature-dependent aminoglycoside resistance in Stenotrophomonas (Xanthomonas) maltophilia; alterations in protein and lipopolysaccharide with growth temperature. J Antimicrob Chemother 37:665–676PubMedCrossRef Rahmati-Bahram A, Magee JT, Jackson SK (1996) Temperature-dependent aminoglycoside resistance in Stenotrophomonas (Xanthomonas) maltophilia; alterations in protein and lipopolysaccharide with growth temperature. J Antimicrob Chemother 37:665–676PubMedCrossRef
58.
Zurück zum Zitat Rahmati-Bahram A, Magee JT, Jackson SK (1997) Effect of temperature on aminoglycoside binding sites in Stenotrophomonas maltophilia. J Antimicrob Chemother 39:19–24PubMedCrossRef Rahmati-Bahram A, Magee JT, Jackson SK (1997) Effect of temperature on aminoglycoside binding sites in Stenotrophomonas maltophilia. J Antimicrob Chemother 39:19–24PubMedCrossRef
59.
Zurück zum Zitat McKay GA, Woods DE, MacDonald KL, Poole K (2003) Role of phosphoglucomutase of Stenotrophomonas maltophilia in lipopolysaccharide biosynthesis, virulence, and antibiotic resistance. Infect Immun 71:3068–3075PubMedCrossRef McKay GA, Woods DE, MacDonald KL, Poole K (2003) Role of phosphoglucomutase of Stenotrophomonas maltophilia in lipopolysaccharide biosynthesis, virulence, and antibiotic resistance. Infect Immun 71:3068–3075PubMedCrossRef
60.
Zurück zum Zitat Magnet S, Blanchard JS (2005) Molecular insights into aminoglycoside action and resistance. Chem Rev 105:477–497PubMedCrossRef Magnet S, Blanchard JS (2005) Molecular insights into aminoglycoside action and resistance. Chem Rev 105:477–497PubMedCrossRef
61.
Zurück zum Zitat Barbolla R, Catalano M, Orman BE, Famiglietti A, Vay C, Smayevsky J, Centron D, Piñeiro S (2004) Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob Agents Chemother 48:666–669PubMedCrossRef Barbolla R, Catalano M, Orman BE, Famiglietti A, Vay C, Smayevsky J, Centron D, Piñeiro S (2004) Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob Agents Chemother 48:666–669PubMedCrossRef
62.
Zurück zum Zitat Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284:1318–1322PubMedCrossRef Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284:1318–1322PubMedCrossRef
63.
Zurück zum Zitat Clinical and Laboratory Standards Institute (2006) Performance standards for antimicrobial susceptibility testing: 16th informational supplement M100-S16. CLSI, Wayne, PA Clinical and Laboratory Standards Institute (2006) Performance standards for antimicrobial susceptibility testing: 16th informational supplement M100-S16. CLSI, Wayne, PA
64.
Zurück zum Zitat Yao JD, Louie M, Louie L, Goodfellow J, Simor AE (1995) Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas maltophilia. J Clin Microbiol 33:1428–1430PubMed Yao JD, Louie M, Louie L, Goodfellow J, Simor AE (1995) Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas maltophilia. J Clin Microbiol 33:1428–1430PubMed
65.
Zurück zum Zitat Fadda G, Spanu T, Ardito F, Taddei C, Santangelo R, Siddu A, Ciccaglione D, Italian Epimiological Observatory (2004) Antimicrobial resistance among non-fermentative gram-negative bacilli isolated from the respiratory tracts of Italian inpatients: a 3-year surveillance study by the Italian Epidemiological Survey. Int J Antimicrob Agents 23:254–261PubMedCrossRef Fadda G, Spanu T, Ardito F, Taddei C, Santangelo R, Siddu A, Ciccaglione D, Italian Epimiological Observatory (2004) Antimicrobial resistance among non-fermentative gram-negative bacilli isolated from the respiratory tracts of Italian inpatients: a 3-year surveillance study by the Italian Epidemiological Survey. Int J Antimicrob Agents 23:254–261PubMedCrossRef
66.
Zurück zum Zitat Jones RN, Sader HS, Beach ML (2003) Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18,569 strains non-fermentative gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (19972001). Int J Antimicrob Agents 22:551–556PubMedCrossRef Jones RN, Sader HS, Beach ML (2003) Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18,569 strains non-fermentative gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (19972001). Int J Antimicrob Agents 22:551–556PubMedCrossRef
67.
Zurück zum Zitat Betriu C, Rodríguez-Avial I, Sánchez BA, Gómez M, Picazo JJ (2002) Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 50:758–759PubMedCrossRef Betriu C, Rodríguez-Avial I, Sánchez BA, Gómez M, Picazo JJ (2002) Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 50:758–759PubMedCrossRef
68.
Zurück zum Zitat Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J (2001) Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis 32(Suppl 2):104–113CrossRef Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J (2001) Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis 32(Suppl 2):104–113CrossRef
69.
Zurück zum Zitat Herrero Romero M, Gómez Gómez MJ, Pachón Diaz J, Cisneros Herreros JM (2000) Bacteremias por Stenotrophomonas maltophilia: epidemiologia, caracteristicas clinicas y factores pronósticos. Rev Clín Esp 200:315–317PubMed Herrero Romero M, Gómez Gómez MJ, Pachón Diaz J, Cisneros Herreros JM (2000) Bacteremias por Stenotrophomonas maltophilia: epidemiologia, caracteristicas clinicas y factores pronósticos. Rev Clín Esp 200:315–317PubMed
70.
Zurück zum Zitat Schmitz FJ, Sadurski R, Verhoef J, Milatovic D, Fluit AC (2000) Typing of 154 clinical isolated of Stenotrophomonas maltophilia by pulsed-field gel electrophoresis and determination of the in vitro susceptibilities of these strains to 28 antibiotics. J Antimicrob Chemother 45:921–923PubMedCrossRef Schmitz FJ, Sadurski R, Verhoef J, Milatovic D, Fluit AC (2000) Typing of 154 clinical isolated of Stenotrophomonas maltophilia by pulsed-field gel electrophoresis and determination of the in vitro susceptibilities of these strains to 28 antibiotics. J Antimicrob Chemother 45:921–923PubMedCrossRef
71.
Zurück zum Zitat Fass RJ, Barnishan J, Solomon M, Ayres LW (1996) In vitro activities of quinolones, β-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother 40:1412–1418PubMed Fass RJ, Barnishan J, Solomon M, Ayres LW (1996) In vitro activities of quinolones, β-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother 40:1412–1418PubMed
72.
Zurück zum Zitat Arpi M, Victor MA, Mortensen I, Gettschau A, Bruun B (1996) In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods. APMIS 104:108–114PubMed Arpi M, Victor MA, Mortensen I, Gettschau A, Bruun B (1996) In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods. APMIS 104:108–114PubMed
73.
Zurück zum Zitat Laing FP, Ramotar K, Read RR, Alfieri N, Kureishi A, Hendersen EA, Louie TJ (1995) Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol 33:513–518PubMed Laing FP, Ramotar K, Read RR, Alfieri N, Kureishi A, Hendersen EA, Louie TJ (1995) Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol 33:513–518PubMed
74.
Zurück zum Zitat Felegie TP, Yu VL, Rumans LW, Yee RB (1979) Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination. Antimicrob Agents Chemother 16:833–837PubMed Felegie TP, Yu VL, Rumans LW, Yee RB (1979) Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination. Antimicrob Agents Chemother 16:833–837PubMed
75.
Zurück zum Zitat Traub WH, Leonhard B, Bauer D (1998) Antibiotic susceptibility of Stenotrophomonas (Xanthomonas) maltophilia: comparative (NCCLS criteria) evaluation of antimicrobial drugs with the agar dilution and the agar disk diffusion (Bauer-Kirby) tests. Chemotherapy 44:164–173PubMedCrossRef Traub WH, Leonhard B, Bauer D (1998) Antibiotic susceptibility of Stenotrophomonas (Xanthomonas) maltophilia: comparative (NCCLS criteria) evaluation of antimicrobial drugs with the agar dilution and the agar disk diffusion (Bauer-Kirby) tests. Chemotherapy 44:164–173PubMedCrossRef
76.
Zurück zum Zitat Maningo E, Watanakunakorn C (1995) Xanthomonas maltophilia and Pseudomonas cepacia in lower respiratory tracts of patients in critical care units. J Infect 31:89–92PubMedCrossRef Maningo E, Watanakunakorn C (1995) Xanthomonas maltophilia and Pseudomonas cepacia in lower respiratory tracts of patients in critical care units. J Infect 31:89–92PubMedCrossRef
77.
Zurück zum Zitat Traub WH, Leonhard B, Bauer D (1998) Stenotrophomonas (Xanthomonas) maltophilia: in vitro susceptibility to selected antimicrobial drugs, single and combined, with and without defibrinated human blood. Chemotherapy 44:293–304PubMedCrossRef Traub WH, Leonhard B, Bauer D (1998) Stenotrophomonas (Xanthomonas) maltophilia: in vitro susceptibility to selected antimicrobial drugs, single and combined, with and without defibrinated human blood. Chemotherapy 44:293–304PubMedCrossRef
78.
Zurück zum Zitat Sader HS, Jones RN (2005) Antimicrobial susceptibility of uncommonly isolated non-enteric gram-negative bacilli. Int J Antimicrob Agents 25:95–109PubMedCrossRef Sader HS, Jones RN (2005) Antimicrobial susceptibility of uncommonly isolated non-enteric gram-negative bacilli. Int J Antimicrob Agents 25:95–109PubMedCrossRef
79.
Zurück zum Zitat Carroll KC, Cohen S, Nelson R, Campbell DM, Claridge JD, Garrison MW, Kramp J, Malone C, Hoffmann M, Anderson DE (1998) Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 32:229–235PubMedCrossRef Carroll KC, Cohen S, Nelson R, Campbell DM, Claridge JD, Garrison MW, Kramp J, Malone C, Hoffmann M, Anderson DE (1998) Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 32:229–235PubMedCrossRef
80.
Zurück zum Zitat Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S (2000) Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 32:651–656PubMedCrossRef Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S (2000) Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 32:651–656PubMedCrossRef
81.
Zurück zum Zitat Lecso-Bornet M, Bergogne-Berezin E (1997) Susceptibility of 100 strains of Stenotrophomonas maltophilia to three β-lactam and five beta-lactam-beta-lactamase inhibitor combinations. J Antimicrob Chemother 40:717–720PubMedCrossRef Lecso-Bornet M, Bergogne-Berezin E (1997) Susceptibility of 100 strains of Stenotrophomonas maltophilia to three β-lactam and five beta-lactam-beta-lactamase inhibitor combinations. J Antimicrob Chemother 40:717–720PubMedCrossRef
82.
Zurück zum Zitat Muñoz Bellido JL, Muñoz Criado S, Garcia Garcia I, AlonsoManzanares MA, Gutierrez Zufiaurre MN, Garcia-Reodriguez JA (1997) In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity. Antimicrob Agents Chemother 41:2612–2615PubMed Muñoz Bellido JL, Muñoz Criado S, Garcia Garcia I, AlonsoManzanares MA, Gutierrez Zufiaurre MN, Garcia-Reodriguez JA (1997) In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity. Antimicrob Agents Chemother 41:2612–2615PubMed
83.
Zurück zum Zitat Pankuch GA, Jacobs MR, Rittenhouse SF, Appelbaum PC (1994) Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob Agents Chemother 38:2317–2322PubMed Pankuch GA, Jacobs MR, Rittenhouse SF, Appelbaum PC (1994) Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob Agents Chemother 38:2317–2322PubMed
84.
Zurück zum Zitat Garcia Rodriguez JA, Garcia Sanchez JE, Garcia Garcia MI, Garcia Sanchez E, Muñoz Bellido JL (1991) Antibiotic susceptibility profile of Xanthomonas maltophilia in vitro activity of β-lactam/beta-lactamase inhibitor combinations. Diagn Microbiol Infect Dis 14:239–243PubMedCrossRef Garcia Rodriguez JA, Garcia Sanchez JE, Garcia Garcia MI, Garcia Sanchez E, Muñoz Bellido JL (1991) Antibiotic susceptibility profile of Xanthomonas maltophilia in vitro activity of β-lactam/beta-lactamase inhibitor combinations. Diagn Microbiol Infect Dis 14:239–243PubMedCrossRef
85.
Zurück zum Zitat Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K (1994) A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 38:624–627PubMed Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K (1994) A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 38:624–627PubMed
86.
Zurück zum Zitat Garrison MW, Anderson DE, Campbell DM, Carroll KC, Malone CL, Anderson JD, Hallis RJ, Pfaller MA (1996) Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 40:2859–2864PubMed Garrison MW, Anderson DE, Campbell DM, Carroll KC, Malone CL, Anderson JD, Hallis RJ, Pfaller MA (1996) Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 40:2859–2864PubMed
87.
Zurück zum Zitat Garcia Rodriguez JA, Garcia Sanchez JE, Muñoz Bellido JL, Muñoz Bellido JL, Garcia Garcia MI (1991) Kinetics of antimicrobial activity of aztreonam/clavulanic acid (2:1) against Xanthomonas maltophilia. J Antimicrob Chemother 27:552–554PubMedCrossRef Garcia Rodriguez JA, Garcia Sanchez JE, Muñoz Bellido JL, Muñoz Bellido JL, Garcia Garcia MI (1991) Kinetics of antimicrobial activity of aztreonam/clavulanic acid (2:1) against Xanthomonas maltophilia. J Antimicrob Chemother 27:552–554PubMedCrossRef
88.
Zurück zum Zitat Sader HS, Pignatari AC, Frei R, Hollis RJ, Jones RN (1994) Pulsed-field gel electrophoresis of restriction-digested genomic DNA and antimicrobial susceptibility of Xanthomonas maltophilia strains from Brazil, Switzerland and the USA. J Antimicrob Chemother 33:615–618PubMedCrossRef Sader HS, Pignatari AC, Frei R, Hollis RJ, Jones RN (1994) Pulsed-field gel electrophoresis of restriction-digested genomic DNA and antimicrobial susceptibility of Xanthomonas maltophilia strains from Brazil, Switzerland and the USA. J Antimicrob Chemother 33:615–618PubMedCrossRef
89.
Zurück zum Zitat Khardori N, Elting L, Wong E, Schable B, Bodey GP (1990) Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 12:997–1003PubMed Khardori N, Elting L, Wong E, Schable B, Bodey GP (1990) Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 12:997–1003PubMed
90.
Zurück zum Zitat Gales AC, Reis AO, Jones RN (2001) Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39:183–190PubMedCrossRef Gales AC, Reis AO, Jones RN (2001) Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39:183–190PubMedCrossRef
91.
Zurück zum Zitat Howe RA, Wilson MP, Walsh TR, Millar MR (1997) Susceptibility testing of Stenotrophomonas maltophilia to carbapenems. J Antimicrob Chemother 40:13–17PubMedCrossRef Howe RA, Wilson MP, Walsh TR, Millar MR (1997) Susceptibility testing of Stenotrophomonas maltophilia to carbapenems. J Antimicrob Chemother 40:13–17PubMedCrossRef
92.
Zurück zum Zitat Gesu GP, Marchetti F, Piccoli L, Cavallero A (2003) Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 47:816–819PubMedCrossRef Gesu GP, Marchetti F, Piccoli L, Cavallero A (2003) Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 47:816–819PubMedCrossRef
93.
Zurück zum Zitat Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H (2000) Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 45:363–365PubMedCrossRef Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H (2000) Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 45:363–365PubMedCrossRef
94.
Zurück zum Zitat Biedenbach DJ, Croco MA, Barrett TJ, Jones RN (1999) Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods. Eur J Clin Microbiol Infect Dis 18:428–431PubMedCrossRef Biedenbach DJ, Croco MA, Barrett TJ, Jones RN (1999) Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods. Eur J Clin Microbiol Infect Dis 18:428–431PubMedCrossRef
95.
Zurück zum Zitat Giamarellos-Bourboulis EJ, Karnesis L, Galani I, Giamarellou H (2002) In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 46:3997–3999PubMedCrossRef Giamarellos-Bourboulis EJ, Karnesis L, Galani I, Giamarellou H (2002) In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 46:3997–3999PubMedCrossRef
96.
Zurück zum Zitat Valdezate S, Vindel A, Loza E, Baquero F, Canton R (2001) Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother 45:1581–1584PubMedCrossRef Valdezate S, Vindel A, Loza E, Baquero F, Canton R (2001) Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother 45:1581–1584PubMedCrossRef
97.
Zurück zum Zitat Pankuch GA, Jacobs MR, Appelbaum PC (1994) Susceptibilities of 123 Xanthomonas maltophilia to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother 38:369–370PubMed Pankuch GA, Jacobs MR, Appelbaum PC (1994) Susceptibilities of 123 Xanthomonas maltophilia to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother 38:369–370PubMed
98.
Zurück zum Zitat Cohn ML, Waites KB (2001) Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies. Antimicrob Agents Chemother 45:2126–2128PubMedCrossRef Cohn ML, Waites KB (2001) Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies. Antimicrob Agents Chemother 45:2126–2128PubMedCrossRef
99.
Zurück zum Zitat Ba BB, Feghali H, Arpin C, Saux MC, Quentin C (2004) Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother 48:946–953PubMedCrossRef Ba BB, Feghali H, Arpin C, Saux MC, Quentin C (2004) Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother 48:946–953PubMedCrossRef
100.
Zurück zum Zitat Saiman L, Chen Y, Gabriel PS, Knirsch C (2002) Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 46:1105–1107PubMedCrossRef Saiman L, Chen Y, Gabriel PS, Knirsch C (2002) Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 46:1105–1107PubMedCrossRef
101.
Zurück zum Zitat Tripodi MF, Andreana A, Sarnataro G, Ragone E, Adinolfi LE, Utili R (2001) Comparative activities of isepamicin, amikacin, cefepime, and ciprofloxacin alone or in combination with other antibiotics against Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 20:73–75PubMedCrossRef Tripodi MF, Andreana A, Sarnataro G, Ragone E, Adinolfi LE, Utili R (2001) Comparative activities of isepamicin, amikacin, cefepime, and ciprofloxacin alone or in combination with other antibiotics against Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 20:73–75PubMedCrossRef
102.
Zurück zum Zitat Milatovic D, Schmitz FJ, Verhoef J, Fluit AC (2003) Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 47:400–404PubMedCrossRef Milatovic D, Schmitz FJ, Verhoef J, Fluit AC (2003) Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 47:400–404PubMedCrossRef
103.
Zurück zum Zitat Sader HS, Jones RN, Dowzicky MJ, Frirische TR (2005) Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 52:203–208PubMedCrossRef Sader HS, Jones RN, Dowzicky MJ, Frirische TR (2005) Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 52:203–208PubMedCrossRef
104.
Zurück zum Zitat Katz E, Demais AL (1977) The peptide antibiotics of Bacillus: chemistry, biogenesis, and possible functions. Bacteriol Rev 41:449–474PubMed Katz E, Demais AL (1977) The peptide antibiotics of Bacillus: chemistry, biogenesis, and possible functions. Bacteriol Rev 41:449–474PubMed
105.
Zurück zum Zitat Newton BA (1956) The properties and mode of action of the polymyxins. Bacteriol Rev 20:14–17PubMed Newton BA (1956) The properties and mode of action of the polymyxins. Bacteriol Rev 20:14–17PubMed
106.
Zurück zum Zitat Schindler M, Osborn MJ (1979) Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 18:4425–4430PubMedCrossRef Schindler M, Osborn MJ (1979) Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 18:4425–4430PubMedCrossRef
107.
Zurück zum Zitat Hermsen ED, Sullivan CJ, Rotschafer JC (2003) Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 17:545–562PubMedCrossRef Hermsen ED, Sullivan CJ, Rotschafer JC (2003) Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 17:545–562PubMedCrossRef
108.
Zurück zum Zitat British Society for Antimicrobial Chemotherapy (2006) BSAC disc diffusion method for antimicrobial susceptibility testing, version 5. http://www.bsac.org.uk. Cited January 2006 British Society for Antimicrobial Chemotherapy (2006) BSAC disc diffusion method for antimicrobial susceptibility testing, version 5. http://​www.​bsac.​org.​uk. Cited January 2006
109.
Zurück zum Zitat Zelenitsky SA, Iacovides H, Ariano RE, Harding GK (2005) Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 51:39–49PubMedCrossRef Zelenitsky SA, Iacovides H, Ariano RE, Harding GK (2005) Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 51:39–49PubMedCrossRef
110.
Zurück zum Zitat Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H (2002) Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 44:259–263PubMedCrossRef Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H (2002) Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 44:259–263PubMedCrossRef
111.
Zurück zum Zitat Muñoz JL, García MI, Muñoz S, Leal S, Fajardo M, Garcia-Rodriguez JA (1996) Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 15:879–882PubMedCrossRef Muñoz JL, García MI, Muñoz S, Leal S, Fajardo M, Garcia-Rodriguez JA (1996) Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 15:879–882PubMedCrossRef
112.
Zurück zum Zitat Dawis MA, Isenberg HD, France KA, Jenkins SG (2003) In vitro activity of gatifloxacin alone and combination with cefepime, meropemem, piperacillin and gentamicin against multidrug-resistant organisms. J Antimicrob Chemother 51:1203–1211PubMedCrossRef Dawis MA, Isenberg HD, France KA, Jenkins SG (2003) In vitro activity of gatifloxacin alone and combination with cefepime, meropemem, piperacillin and gentamicin against multidrug-resistant organisms. J Antimicrob Chemother 51:1203–1211PubMedCrossRef
113.
Zurück zum Zitat Visalli MA, Jacobs MR, Appelbaum PC (1998) Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 42:2002–2005PubMed Visalli MA, Jacobs MR, Appelbaum PC (1998) Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 42:2002–2005PubMed
114.
Zurück zum Zitat Poulos CD, Matsumura SO, Willey BM, Low DE, McGeer A (1995) In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother 39:2220–2223PubMed Poulos CD, Matsumura SO, Willey BM, Low DE, McGeer A (1995) In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother 39:2220–2223PubMed
Metadaten
Titel
Antimicrobial therapy for Stenotrophomonas maltophilia infections
verfasst von
A. C. Nicodemo
J. I. Garcia Paez
Publikationsdatum
01.04.2007
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 4/2007
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0279-3

Weitere Artikel der Ausgabe 4/2007

European Journal of Clinical Microbiology & Infectious Diseases 4/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.